ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ImmuCell Corporation (ICCC) reported Q2 2026 product sales of $7.19 million, up 11.5% year-over-year, with earnings of 20 cents per share versus 6 cents prior year. However, gross margins contracted significantly to 33.9% from 43.7% due to lower production volumes, material quality issues, and cost reclassifications. The stock declined 8.8% post-earnings. Management highlighted strong domestic sales growth of 27.7% and increased market share for First Defense, but noted international headwinds and manufacturing challenges. The company is investing $8 million in facility expansion expected to triple capacity by end of 2027.
Read original at zacks-investment-research